Amundi Asset Management US’s AC Immune ACIU Stock Holding History

Amundi Asset Management US’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,500	Closed	-$45K	–	1537
2017 Q4	$45K	Buy	+3,500	New	+$41.2K	﹤0.01%	1501

Other funds holding ACIU

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Asset Management US's ACIU Position: Q1 2018 in Review

Amundi Asset Management US sold out of AC Immune (ACIU) in Q1 2018, closing a stake of 3,500 shares — an estimated $45K sold.

Amundi Asset Management US first reported a position in ACIU in Q4 2017 and held it in 1 quarter. The position peaked at $45K in Q4 2017. 18 funds tracked by Wall St. Rank hold ACIU as of Q1 2018.

Amundi Asset Management US reported no remaining AC Immune position as of Q1 2018 after selling out during the quarter.
Amundi Asset Management US sold 3,500 AC Immune shares in Q1 2018, an estimated $45K.
Amundi Asset Management US first reported a position in AC Immune in Q4 2017 and held it in 1 quarter.
Amundi Asset Management US's AC Immune position peaked at $45K in Q4 2017.
18 funds tracked by Wall St. Rank held AC Immune as of Q1 2018.

Based on Amundi Asset Management US's 13F filing for Q1 2018, filed 15 May 2018.